Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 4Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Recurrence 1Myeloproliferative Disorders 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Dexamethasone 18Cyclophosphamide 16fludarabine 11pomalidomide 9pembrolizumab 9carfilzomib 9daratumumab 7Rituximab 7Lenalidomide 7Calcium Dobesilate 7fludarabine phosphate 6Gemcitabine 6Cisplatin 6Bortezomib 6venetoclax 5elotuzumab 4isatuximab 3blinatumomab 3Vincristine 3Radiotherapy 3Prednisone 3Letrozole 3Etoposide 3Doxorubicin 3Cytarabine 3tisagenlecleucel 2selinexor 2ruxolitinib 2palbociclib 2ixazomib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Recurrence × quizartinib × Clear all
NCT03793478 2026-04-01

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Daiichi Sankyo

Phase 1/2 Active not recruiting
65 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡